Dermata Therapeutics, Inc. (DRMA)
|Address:3525 Del Mar Heights Rd., #322
San Diego, CA 92130
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
Dermata Therapeutics is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions.
Our Spongilla technology platform is based on the use of a naturally growing freshwater sponge, Spongilla lacustris, or Spongilla. Traditionally, locals would harvest the sponge to be used as a folk medicine to treat various inflammatory ailments, but research has been conducted to evaluate the use of Spongilla for the possible treatment of various skin diseases and aesthetic conditions.
Our lead product candidate, DMT310, a once-weekly topical product, is the first product candidate being developed from our Spongilla technology platform.
Based on DMT310’s multiple mechanisms of action, it is currently under clinical development for the treatment of acne vulgaris (or acne), psoriasis vulgaris (or psoriasis), and papulopustular rosacea.
We recently received results from our Phase 2b clinical trial of DMT310 for the treatment of moderate-to-severe acne. This trial produced statistically significant results for all efficacy endpoints.
The clinical endpoints used in the Phase 2b trial are identical to those endpoints we intend to use in our two Phase 3 acne clinical trials, which trials we believe will form the basis of our new drug application for DMT310.
|Gerald T. Proehl||President, Chief Executive Officer and Chairman|
|Thomas H. Insley||Chief Financial Officer|
|Christopher J. Nardo, M.P.H., Ph.D.||Senior Vice President, Development|
|Maria Bedoya Toro Munera, Ph.D., M.B.A.||Senior Vice President, Regulatory Affairs & Quality Assurance|
|David Hale||Lead Director|
|Wendell Wierenga, Ph.D.||Director|
|Stephen J. Mento, Ph.D.||Director|
Latest SEC Filings
|Jul 12, 2021||FWP||Filing under Securities Act Rules 163/433 of free writing prospectuses|
|Jul 9, 2021||S-1/A||General form for registration of securities under the Securities Act of 1933|
|Jul 2, 2021||S-1/A||General form for registration of securities under the Securities Act of 1933|
|Jun 10, 2021||S-1||General form for registration of securities under the Securities Act of 1933|
|May 7, 2021||DRS/A||Draft Registration Statement|
|Apr 2, 2021||DRS||Draft Registration Statement|
|View All SEC filings|